See you at Plant, Animal Genomics (PAG33) in San Diego!

Annogen is thrilled to announce our participation in the upcoming Plant & Animal Genome (PAG 33) conference, taking place from January 10-14, 2026, in beautiful San Diego, California!

As the trusted partner for advanced crop and animal engineering, we are eager to connect with fellow researchers, collaborators, and potential partners, showcasing our cutting-edge promoter discovery platform that unlocks gain-of-function mutation screening at the scale of 10,000s in a single experiment.

The PAG conference is a cornerstone event for the global genomics and breeding community, bringing together experts from academia, industry, and regulatory bodies to share the latest breakthroughs and foster new collaborations. It’s an invaluable opportunity to discuss the future of genomic technologies and crop/animal improvement, and we are excited to be a part of these crucial conversations.

We invite you to schedule a meeting to learn more about how Annogen can support your research and development efforts. Our team will be on hand to discuss our platform, answer your questions, and explore potential collaborations.

We are also proud to be presenting a scientific posters at PAG33, highlighting recent advancements and case studies for respectively KWS and Keygene, including their in planta validations of variants identified by SuRE. 

See you in San Diego!

 

VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2

VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2

VectorY Therapeutics has received clearance from the U.S. FDA to begin its PIONEER-ALS Phase 1/2 Trial for VTx-002. This is a special type of antibody therapy designed to fight the root cause of most ALS cases: a faulty protein called TDP-43 . The VTx-002 treatment uses a harmless virus (AAV5.2 capsid) to deliver instructions to the body’s cells, turning them into tiny factories that continuously produce the therapeutic antibody. This allows the treatment to keep working after just one dose. A key piece of the instruction manual that ensures this continuous production is the promoter, which acts like an “on” switch for the antibody gene, and this vital component was developed by Annogen. The study will test the safety of VTx-002, which is designed to clean up toxic TDP-43 and help sick motor neurons recover.

Annogen Heads to London for the Advanced Therapies Congress 2026

Annogen Heads to London for the Advanced Therapies Congress 2026

Annogen today announced a research collaboration with Orchard Therapeutics, a global gene therapy leader, for the identification of immune cell-specific human promoters for use in certain pre-clinical hematopoietic stem cell (HSC) gene therapy programs.

Technology

 

Solutions

 

Annogen